RxDoctor Payments Data

Peggy Jesse

Family · Anchorage, AKNPI 1790811057

Payments from drug & device makers

$1,088in general payments, 2019–2025

Across 41 payments — averaging $26.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$334
  • AbbVie$210
  • E.r. Squibb & Sons, L.L.C.$122
  • Pfizer$118
  • Otsuka America Pharmaceutical, Inc.$78
  • Amgen$47
  • plus $179 from 8 others

What the payments were for

  • Food & beverage$1,088100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,088 in reported general payments places this provider in the 75th percentile of 315 family providers in Alaska.

See all family providers in Alaska

Medicare billing

Part B allowed, 2024
$100,948
Medicare patients
390
Services billed
2,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide40$49,662
TrulicityDulaglutide24$34,792
MounjaroTirzepatide13$12,152
Breo ElliptaFluticasone/Vilanterol11$6,859
Albuterol Sulfate HfaAlbuterol Sulfate49$2,371
SynthroidLevothyroxine Sodium23$1,877
Atorvastatin Calcium139$1,628
PaxlovidNirmatrelvir/Ritonavir13$1,367
Rosuvastatin Calcium47$1,348
Ketoconazole47$1,303
Gabapentin52$1,225
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide15$1,216
Pantoprazole Sodium55$1,149
Irbesartan23$1,028
Levothyroxine Sodium91$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$334$49,66240 claims
Lilly USA, LLCTrulicity, Mounjaro$21$46,94437 claims
GSKBreo Ellipta$24$6,85911 claims
AbbVieSynthroid$210$1,87723 claims
PfizerPaxlovid$118$1,36713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 315 family providers in Alaska.

Other family in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →